ethyl 5-(2-nitrophenyl)-2-phenyloxazole-4-carboxylate | 587884-70-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: ethyl 5-(2-nitrophenyl)-2-phenyloxazole-4-carboxylate
• 英文别名: Ethyl 5-(2-nitrophenyl)-2-phenyl-1,3-oxazole-4-carboxylate；ethyl 5-(2-nitrophenyl)-2-phenyl-1,3-oxazole-4-carboxylate
• CAS: 587884-70-6
• 化学式: C₁₈H₁₄N₂O₅
• 分子量: 338.32
• InChiKey: CQBMKNCXZOAFFD-UHFFFAOYSA-N

物化性质

• 熔点：
  136-137 °C
• 沸点：
  523.2±60.0 °C(Predicted)
• 密度：
  1.289±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  25
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  98.2
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  ethyl 5-(2-nitrophenyl)-2-phenyloxazole-4-carboxylate 在 palladium on activated carbon 、 氢气 、 potassium carbonate 作用下， 以 甲醇 、 乙二醇二甲醚 、 N,N-二甲基甲酰胺 为溶剂， 90.0~130.0 ℃ 、344.75 kPa 条件下， 反应 16.0h， 生成 5-methyl-2-phenyl-oxazolo<4,5-c>quinolin-4(5H)-one
  参考文献：
  名称：

  恶唑并[4,5-c]-喹啉酮类似物作为新型白细胞介素33抑​​制剂的合理设计、合成和评价

  摘要：

  的恶唑并[4,5-C] -喹啉酮类似物7  Ç是白细胞介素33的第一小分子抑制剂，其结合至IL-33和ST2的在2D NMR研究的接口和白细胞介素的强抑制证明-6 在人类肥大细胞中产生。

  DOI：

  10.1002/asia.202100896
• 作为产物：
  描述：

  2-氯恶唑-4-羧酸乙酯 在 四(三苯基膦)钯 、 palladium diacetate 、 potassium carbonate 、 caesium carbonate 、 三苯基膦 作用下， 以 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 4.0h， 生成 ethyl 5-(2-nitrophenyl)-2-phenyloxazole-4-carboxylate
  参考文献：
  名称：

  恶唑并[4,5-c]-喹啉酮类似物作为新型白细胞介素33抑​​制剂的合理设计、合成和评价

  摘要：

  的恶唑并[4,5-C] -喹啉酮类似物7  Ç是白细胞介素33的第一小分子抑制剂，其结合至IL-33和ST2的在2D NMR研究的接口和白细胞介素的强抑制证明-6 在人类肥大细胞中产生。

  DOI：

  10.1002/asia.202100896

文献信息

• Palladium-Catalyzed Direct (Hetero)arylation of Ethyl Oxazole-4-carboxylate: An Efficient Access to (Hetero)aryloxazoles
  作者：Cécile Verrier、Thibaut Martin、Christophe Hoarau、Francis Marsais

  DOI：10.1021/jo801093n

  日期：2008.9.19

  toward 2-(hetero)arylated and 2,5-di(hetero)arylated oxazoles through regiocontrolled palladium-catalyzed direct (hetero)arylation of ethyl oxazole-4-carboxylate with iodo-, bromo-, and chloro(hetero)aromatics followed by a two-step hydrolysis/decarboxylation sequence was described. The method was applied here to a neat synthesis of two 2,5-di(hetero)aryloxazole natural products, balsoxin and texaline

  通过区域控制的钯催化的恶唑-4-羧酸乙酯与碘，溴和氯（杂）的直接（杂）芳基化反应，生成2-（杂）芳基化和2,5-二（杂）芳基恶唑的直接途径描述了芳族化合物，随后是两步水解/脱羧序列。该方法在这里用于两种2,5-二（杂）芳基恶唑天然产物balsoxin和texaline的纯净合成。
• NOVEL QUINOLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIC DERMATITIS INCLUDING THE QUINOLINONE DERIVATIVE AS ACTIVE INGREDIENT
  申请人：Korea University Research and Business Foundation, Sejong Campus

  公开号：US20200140457A1

  公开（公告）日：2020-05-07

  The present invention relates to anovel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The quinolinone derivative compound of the present invention can effectively suppress inflammatory responses of allergic diseases such as asthma or atopic dermatitis. The present invention also relates to a pharmaceutical composition including the quinolinone derivative compound. The pharmaceutical composition of the present invention can be used to fundamentally prevent or treat various allergic and asthmatic diseases.

  本发明涉及一种新型喹诺酮衍生物化合物，通过调节由TSLP和IL-33介导的细胞内信号传导，以在预防或治疗哮喘或特应性皮炎等过敏疾病中发挥功效。本发明的喹诺酮衍生物化合物可以有效抑制哮喘或特应性皮炎等过敏疾病的炎症反应。本发明还涉及包括喹诺酮衍生物化合物的药物组合物。本发明的药物组合物可用于根本预防或治疗各种过敏和哮喘疾病。
• NOVEL QUINOLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ALLERGIC DISEASE SUCH AS ASTHMA OR ATOPY COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：Korea University Research and Business Foundation, Sejong Campus

  公开号：EP3567044A1

  公开（公告）日：2019-11-13

  The present invention relates to a novel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The quinolinone derivative compound of the present invention can effectively suppress inflammatory responses of allergic diseases such as asthma or atopic dermatitis. The present invention also relates to a pharmaceutical composition including the quinolinone derivative compound. The pharmaceutical composition of the present invention can be used to fundamentally prevent or treat various allergic and asthmatic diseases.

  本发明涉及一种新型喹啉酮衍生物化合物，该化合物可调节由 TSLP 和 IL-33 介导的细胞内信号转导，从而在预防或治疗哮喘或特应性皮炎等过敏性疾病方面发挥功效。 本发明的喹啉酮衍生物化合物可有效抑制哮喘或特应性皮炎等过敏性疾病的炎症反应。 本发明还涉及一种包括喹啉酮衍生物化合物的药物组合物。 本发明的药物组合物可用于从根本上预防或治疗各种过敏性疾病和哮喘疾病。
• Quinolinone derivative and pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopic dermatitis including the quinolinone derivative as active ingredient
  申请人：Azcuris Co., Ltd.

  公开号：US11168094B2

  公开（公告）日：2021-11-09

  The present invention relates to a novel quinolinone derivative compound that regulates intracellular signal transduction mediated by TSLP and IL-33 to exhibit efficacy in preventing or treating allergic diseases such as asthma or atopic dermatitis. The quinolinone derivative compound of the present invention can effectively suppress inflammatory responses of allergic diseases such as asthma or atopic dermatitis. The present invention also relates to a pharmaceutical composition including the quinolinone derivative compound. The pharmaceutical composition of the present invention can be used to fundamentally prevent or treat various allergic and asthmatic diseases.

  本发明涉及一种新型喹啉酮衍生物化合物，该化合物可调节由 TSLP 和 IL-33 介导的细胞内信号转导，从而在预防或治疗哮喘或特应性皮炎等过敏性疾病方面发挥功效。本发明的喹啉酮衍生物化合物可有效抑制哮喘或特应性皮炎等过敏性疾病的炎症反应。本发明还涉及一种包括喹啉酮衍生物化合物的药物组合物。本发明的药物组合物可用于从根本上预防或治疗各种过敏性疾病和哮喘疾病。
• Synthesis of 2-Aryl-oxazolo[4,5-<i>c</i>]quinoline-4(5<i>H</i>)-ones and 2-Aryl-thiazolo[4,5-<i>c</i>]quinoline-4(5<i>H</i>)-ones
  作者：Kevin J. Hodgetts、Mark T. Kershaw

  DOI：10.1021/ol0350285

  日期：2003.8.1

  graphicsNovel and highly efficient syntheses of oxazolo[4,5-c]quinoline-4(5H)-ones (1) and thiazolo[4,5-c]quinoline-4(5H)-ones (2) from ethyl 2-chlorooxazole-4-carboxylate (4) and ethyl 2-bromo-5-chlorothiazole-4-carboxylate (13), respectively, are described.